FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015

Share Article

On Tuesday, Aug. 18, FDAnews will present two top attorneys — and experts on these topics — from nationally-recognized law firm Alston & Bird in a webinar titled Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications. Firm partners Julie Tibbets and Matthew Mamak will discuss and comment on the tricky issues surrounding the laws and regulations the FDA and SEC must enforce.

Talking About Your Product Pipeline:
How FDA and SEC Regulate Life Sciences Communications
**FDAnews Webinar**
Aug. 18, 2015 — 1:30 p.m. – 3:00 p.m. EDT
http://www.fdanews.com/productpipeline

When a company has a product in development, whether drug, device or biotech, what they can — and can’t — say about it is tightly regulated by the FDA.

At the same time, the SEC requires that information of material value to investors be properly disclosed to them.

Of course, this SEC requirement involves exactly the same products manufacturers have in the pipeline, the ones that the FDA wants them to be very careful about discussing.

How do manufacturers balance these seemingly contradictory demands?

And further, how do they correctly use all the forms of “communication” available today, including tweets, talking points, press releases, presentations to investors and even "likes" on Facebook?

On Tuesday, Aug. 18, FDAnews will present two top attorneys — and experts on these topics — from nationally-recognized law firm Alston & Bird in a webinar titled Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications.

Firm partners Julie Tibbets and Matthew Mamak will discuss and comment on the tricky issues surrounding the laws and regulations the FDA and SEC must enforce.

In just 90 minutes, attendees will gain a fuller understanding of what exactly their responsibilities are and how to execute them without making mistakes that could damage the company's reputation and bottom line.

Ms. Tibbets and Mr. Mamak will also provide specifics that will help attendees navigate their way through these treacherous regulatory waters:

  •     6 do’s and 6 don’ts for speaking publicly about a product in development
  •     4 do’s and 3 don’ts when talking with analysts and investors
  •     Examples from case studies about communication that resulted in FDA enforcement actions, SEC penalties, and investor lawsuits

At the end of this webinar, attendees will be able to confidently account for the various perspectives — regulators on both sides, investors and the general public — and ensure the right people get the information they should every time.

Register now for Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications on Tuesday, Aug. 18, 2015.

Meet the Presenters:
Julie Tibbets is a partner in Alston & Bird’s Food, Drug & Device/FDA Group. She has built her practice around all aspects of FDA-regulated product branding, advertising, promotion and corporate communications, advising developers, manufacturers and marketers of FDA-regulated products on the regulatory risks and opportunities of their current product messaging.

Matthew Mamak is a partner in Alston & Bird’s Financial Services & Products Group. He regularly advises public and private companies and investment vehicles on capital structuring and raising, corporate governance, and securities regulation and compliance issues.

Who Will Benefit:

  •     Senior management
  •     Legal
  •     PR
  •     Regulatory affairs
  •     Anyone who might be talking to people outside the company (general public, the media, investors) about a product in development

Conference Details:
Talking About Your Product Pipeline:
How FDA and SEC Regulate Life Sciences Communications
**FDAnews Webinar**
Aug. 18, 2015 — 1:30 p.m. – 3:00 p.m. EDT
http://www.fdanews.com/productpipeline

Tuition:
$287 per site
Easy Ways to Register:
Online: http://www.fdanews.com/productpipeline
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDANEWS
+1 (703) 538-7665
Email >
FDAnews
Like >
Visit website